Post-TKA abelacimab reduced VTE at 8 to 12 d compared with enoxaparin.
Where this comes from
- Record sourced from PubMed, PMID 34871049.
- Also identified by DOI 10.7326/ACPJ202112210-136.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Verhamme P, Yi BA, Segers A, et al. <b>Abelacimab for prevention of venous thromboembolism.</b> N Engl J Med. 2021;385:609-17. 34297496.
Medical subject headings
- Arthroplasty, Replacement, Knee
- Venous Thromboembolism